Table 3. Disease Response to Treatment With Mycophenolatea.
| Disease response | Patients, No./total No. (%) | ||
|---|---|---|---|
| Initial treatment with mycophenolate | Addition of mycophenolate | All | |
| At 3-6 mob | |||
| Progressive disease | 1/11 (9) | 6/62 (10) | 7/73 (10) |
| Stable disease | 2/11 (18) | 20/62 (32) | 22/73 (30) |
| Improved disease | 8/11 (73) | 36/62 (58) | 44/73 (60) |
| Beneficial responsec | 10/11 (91) | 56/62 (90) | 66/73 (90) |
| At 9-12 mod | |||
| Progressive disease | 0/8 (0) | 7/46 (15) | 7/54 (13) |
| Stable disease | 1/8 (13) | 13/46 (28) | 14/54 (26) |
| Improved disease | 7/8 (88) | 26/46 (57) | 33/54 (61) |
| Beneficial response | 8/8 (100) | 39/46 (85) | 47/54 (87) |
a
Initial patient population included 80 patients; 3 were excluded from analysis (1 still received treatment but for <3-6 months, 1 outlier, and 1 no data available).
b
Four patients were excluded from analysis (2 with an adverse event, 1 lost to follow-up, and 1 no data at 3-6 months).
c
Stable disease plus improved disease.
d
Twenty patients were excluded from analysis (8 still received treatment but for <9-12 months, 5 had an adverse event, 1 experienced insurance difficulties, 1 had a desire to conceive, 1 treatment ineffective, and 4 lost to follow-up).